I. Herrera-Insua

against Enterococcus faecium . ( quinupristin-dalfopristin ) and sparfloxacin Intracellular activities of RP 59500

B. Murray, R. Rakita, I. Herrera-Insua, 1996 .

Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium

B. Murray, R. Rakita, I. Herrera-Insua, 1996, Antimicrobial agents and chemotherapy.

Human Milk Secretory Antibodies against Attaching and Effacing Escherichia coli Antigens

C. Guzmán, G. Ruiz-Palacios, T. Ochoa, 2003, Emerging infectious diseases.

Lactoferrin Protects Rabbits from Shigella flexneri-Induced Inflammatory Enteritis

T. Ochoa, T. Cleary, H. Gómez, 2002, Infection and Immunity.

The effect of antibiotic exposure on adherence to neutrophils of Enterococcus faecium resistant to phagocytosis.

B. Murray, R. Rakita, I. Herrera-Insua, 1997, The Journal of antimicrobial chemotherapy.

Meropenem-induced alteration of the susceptibility of Escherichia coli and Staphylococcus aureus to the bactericidal activity of human polymorphonuclear leucocytes.

P. Martínez, M. Gómez-Lus, I. Herrera-Insua, 1997, The Journal of antimicrobial chemotherapy.

Protective role of human lactoferrin against invasion of Shigella flexneri M90T.

D. Newburg, T. Cleary, I. Herrera-Insua, 2001 .

Intracellular activity of trovafloxacin (CP-99,219) against Enterococcus faecium.

B. Murray, R. Rakita, I. Herrera-Insua, 1997, Journal of Antimicrobial Chemotherapy.

Synergistic effect of azithromycin on the phagocytic killing ofStaphylococcus aureus by human polymorphonuclear leukocytes

C. Ramos, P. Martínez, M. Gómez-Lus, 2005, European Journal of Clinical Microbiology and Infectious Diseases.